VCYT · Veracyte, Inc. · Earnings Call Transcripts & Audio
Market Cap
$3.32B
Shares
80.39M
Veracyte, Inc. Earnings Call Transcripts
Quarterly earnings calls for Veracyte, Inc. (VCYT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲25.2%
$75.59M
−$8.72M
'22 Q3
22-11-02
▲19.2%
$80.30M
−$3.84M
'22 Q4
23-02-22
▲21.6%
$82.42M
−$8.09M
'23 Q1
23-05-04
▲24%
$90.32M
−$8.40M
'23 Q2
23-08-08
▲19.2%
$90.11M
−$29.62M
'23 Q3
23-11-07
▲22.3%
$98.20M
−$28.29M
'23 Q4
24-02-22
▲17.5%
$96.84M
−$1.86M
'24 Q1
24-05-07
▲26.7%
$114.43M
$5.73M
'24 Q2
24-08-06
▲28.6%
$115.86M
$15.15M
'24 Q3
24-11-06
▲20.8%
$118.63M
$5.11M
'24 Q4
25-02-24
▲18.2%
$114.47M
$7.05M
'25 Q1
25-05-07
▲13.8%
$130.16M
−$980,000
'25 Q2
25-08-06
▲13.8%
$131.87M
$19.14M
'25 Q3
25-11-04
▲18.5%
$140.64M
$41.15M
'25 Q4
26-02-25
▲21.5%
$139.07M
$28.71M
'26 Q1
26-05-05
LATEST
▲15.5%
$150.32M
$25.49M
'26 Q2
26-07-30
Conference
Investor event
2026-09-15
Veracyte, Inc. (VCYT) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-11
Veracyte, Inc. (VCYT) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Confident tone
Decipher prostate growth across risk categories
ProSigna LDT launch in breast cancer
Commercial expansion and sales force investment
Revenue
$150.32M
▲ 15.5% YoY Diluted EPS
$0.31
Gross margin
72.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Veracyte, Inc. (VCYT) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
Veracyte, Inc. (VCYT) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
Confident tone
Decipher Prostate Growth
Afirma Thyroid Franchise
Prosigna LDT Launch
Revenue
$139.07M
▲ 21.5% YoY Diluted EPS
$0.35
▲ 288.9% YoY Gross margin
72.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
Confident tone
Core testing business momentum (Decipher and Affirma)
Clinical evidence and publications
Profitability and cash generation
Revenue
$140.64M*
▲ 18.5% YoY Gross margin
72.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript
Confident tone
Decipher Prostate growth and momentum
TrueMRD / MRD opportunity and platform expansion
Capital allocation, M&A, and 2026 outlook
Revenue
$131.87M
▲ 13.8% YoY Diluted EPS
$0.24
▲ 26.3% YoY Gross margin
69.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript
Confident tone
Decipher Prostate test growth
Prosigna breast cancer test launch
Afirma thyroid test performance
Revenue
$130.16M
▲ 13.8% YoY Diluted EPS
$-0.01
▼ 114.3% YoY Gross margin
69.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript
Confident tone
Decipher Prostate growth and metastatic launch
Afirma franchise and prior period collections headwind
Minimal residual disease (MRD) platform
Revenue
$114.47M
▲ 18.2% YoY Diluted EPS
$0.09
Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-24
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
Confident tone
Decipher Prostate Growth
Financial Performance and Profitability
MRD Platform Development
Revenue
$118.63M*
▲ 20.8% YoY Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Confident tone
Decipher Prostate test growth and evidence
Afirma thyroid test performance and reimbursement
Financial results and profitability
Revenue
$115.86M
▲ 28.6% YoY Diluted EPS
$0.19
Gross margin
68.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript
Confident tone
Afirma Growth
Profitability and Financial Performance
Decipher Prostate Growth
Revenue
$114.43M
▲ 26.7% YoY Diluted EPS
$0.07
Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Veracyte, Inc. (VCYT) Q1 2024 Earnings Call Transcript
Confident tone
Afirma thyroid testing
Long-term growth strategy / IVD and platform expansion
Decipher Prostate testing growth
Revenue
$96.84M
▲ 17.5% YoY Diluted EPS
$-0.02
Gross margin
64.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript
Confident tone
C2i Genomics / MRD acquisition
Afirma franchise momentum
Decipher Prostate growth and evidence
Revenue
$98.20M*
▲ 22.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Veracyte, Inc. (VCYT) Q3 2023 Earnings Call Transcript
Revenue
$90.11M
▲ 19.2% YoY Diluted EPS
$-0.41
Gross margin
64.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Veracyte, Inc. (VCYT) Q2 2023 Earnings Call Transcript
Revenue
$90.32M
▲ 24% YoY Diluted EPS
$-0.12
Gross margin
61.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Veracyte, Inc. (VCYT) Q1 2023 Earnings Call Transcript
Revenue
$82.42M
▲ 21.6% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Veracyte, Inc. (VCYT) Q4 2022 Earnings Call Transcript
Revenue
$80.30M*
▲ 19.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Veracyte, Inc. (VCYT) Q3 2022 Earnings Call Transcript
Revenue
$75.59M
▲ 25.2% YoY Diluted EPS
$-0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Veracyte, Inc. (VCYT) Q2 2022 Earnings Call Transcript
Revenue
$72.86M
▲ 32.2% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Veracyte, Inc. (VCYT) Q1 2022 Earnings Call Transcript
Revenue
$67.78M
▲ 84.7% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Veracyte, Inc. (VCYT) Q4 2021 Earnings Call Transcript
Revenue
$67.34M*
▲ 95% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Veracyte, Inc. (VCYT) Q3 2021 Earnings Call Transcript
Revenue
$60.37M
▲ 94% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Veracyte, Inc. (VCYT) Q2 2021 Earnings Call Transcript
Revenue
$55.10M
▲ 166.2% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-15
Veracyte, Inc. (VCYT) Q1 2021 Earnings Call Transcript
Revenue
$36.70M
▲ 17.9% YoY Diluted EPS
$-0.66
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Veracyte, Inc. (VCYT) Q4 2020 Earnings Call Transcript
Revenue
$34.54M
▲ 16.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Veracyte, Inc. (VCYT) Q3 2020 Earnings Call Transcript
Revenue
$31.12M
▲ 0.5% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Veracyte, Inc. (VCYT) Q2 2020 Earnings Call Transcript
Revenue
$20.70M
▼ 31.3% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-16
Veracyte, Inc. (VCYT) Q1 2020 Earnings Call Transcript
Revenue
$31.12M
▲ 5.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Veracyte, Inc. (VCYT) Q4 2019 Earnings Call
Revenue
$29.73M
▲ 15.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 earnings calls
Key facts
CIK
1384101
CUSIP
92337F107
13F (30d)
144 filings
144 filers
Visit website
Investor relations